Amylyx Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
55 Cambridge Pkwy Ste 6W, Cambridge, Mas...Phone Number
(617) 682-0917Website
www.amylyx.comRevenue
-Stock Symbol
AMLXIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a novel therapeutic for Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease and other neurodegenerative diseases. The company's therapeutic, AMX0035, targets the neuroinflammation and nerve cell death that characterize these diseases. AMX0035 is a proprietary combination of existing compounds that act synergistically to prevent cell death and neurotoxic inflammation in multiple preclinical models.Explore more
Amylyx Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Amylyx Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Amylyx Pharmaceuticals launches new products
Click to see if Amylyx Pharmaceuticals had a recent Job posting/layoffs
Check out if Amylyx Pharmaceuticals is spiking on competitors!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Amylyx Pharmaceuticals has new funding data
Check if Amylyx Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Amylyx Pharmaceuticals recently announced quarterly report
Amylyx Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Amylyx Pharmaceuticals
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Amylyx Pharmaceuticals
Find 2 more new buyers
Compare Similar Companies to Amylyx Pharmaceuticals
Compare insights from companies similar to Amylyx Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Amylyx Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Amylyx Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Amylyx Pharmaceuticals.
Amylyx Pharmaceuticals financials insights
Gather financial insights about Amylyx Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Grant
$3M
Series A
$5M
2017
Debt
$1.8M
2019
Debt
$937K
2020
Debt
$150K
Series B
$30M
2021
Series C
$135M
2022
Stock Offering
$190M
2025
Stock/Share Issuance
$175M
Amylyx Pharmaceuticals Tech Stack
A closer look at the technologies used by Amylyx Pharmaceuticals
Most Recent Scoops
Event
participated in the ENDO 2026 annual meeting in June, where Dr. Colleen Craig presented a poster characterizing the clinical, economic, and humanistic burden of post-bariatric hypoglycemia (PBH) in the U.S., evaluating how level 2 and level 3 hypoglycemic events in PBH impact healthcare utilization, productivity, and overall cost.
Events
Earnings
reported selling, general and administrative expenses of $21.9 million for Q2, compared to $15.6 million in Q2 2025, with the increase primarily attributable to higher legal expenses including a one-time legal charge and investment in commercial strategic initiatives.
Earnings, Spending/Investment, Finance
Project
Amylyx Pharmaceuticals is working on the design of a phase 3 clinical trial for AMX35 in Wolfram syndrome which would be the first phase 3 trial conducted in this multifactorial rare disease following week 96 data from the open-label Helios trial that continued to show stabilization or improvement across glycemic and visual measures.
Medical Research, Clinical Operations
Project
Amylyx Pharmaceuticals News & Media
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public ...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an upsized underwritten public offering of 14,090,000 shares of its common stock at a public offering price of $35.50 per share. In addition, Amylyx has granted the underwriters a 30-day option to purchase up to an additional 2,113,500 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. All of the shares of commonWhy Amylyx Pharmaceuticals Stock Skyrocketed Today
GLP-1 drugs aren't just for weight loss.Amylyx Pharmaceuticals Q2 Earnings Call Highlights
Amylyx Pharmaceuticals (NASDAQ:AMLX) said its pivotal Phase III LUCIDITY trial of avexitide in post-bariatric hypoglycemia, or PBH, has completed final patient visits, with top-line data expected in late August or early September. The company remains blinded to the data and said the trial databaseDid Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Shareholders should contact the...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Amylyx Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a novel therapeutic for Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease and other neurodegenerative diseases. The company's therapeutic, AMX0035, targets the neuroinflammation and nerve cell death that characterize these diseases. AMX0035 is a proprietary co... Read More
